RENE.L Stock - ReNeuron Group plc
Unlock GoAI Insights for RENE.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $530,000 | $403,000 | $257,000 | $6.07M | $49,000 |
| Gross Profit | $263,000 | $79,000 | $-9,246,000 | $-10,270,000 | $-16,197,000 |
| Gross Margin | 49.6% | 19.6% | -3597.7% | -169.3% | -33055.1% |
| Operating Income | $-7,115,000 | $-11,228,000 | $-12,914,000 | $-14,409,000 | $-18,282,000 |
| Net Income | $-5,408,000 | $-9,689,000 | $-11,347,000 | $-11,412,000 | $-14,292,000 |
| Net Margin | -1020.4% | -2404.2% | -4415.2% | -188.2% | -29167.3% |
| EPS | $-0.09 | $-0.17 | $-0.29 | $-0.35 | $-0.44 |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Visit WebsiteEarnings History & Surprises
RENE.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 8, 2023 | — | $-0.05 | — | — |
Q2 2023 | May 25, 2023 | — | $-0.04 | — | — |
Q4 2022 | Dec 2, 2022 | — | $-0.06 | — | — |
Q1 2022 | Mar 31, 2022 | $-0.11 | $-0.08 | +30.9% | ✓ BEAT |
Q3 2021 | Sep 30, 2021 | — | $-0.09 | — | — |
Q1 2021 | Mar 31, 2021 | $-0.13 | $-0.09 | +27.8% | ✓ BEAT |
Q3 2020 | Sep 30, 2020 | — | $-0.18 | — | — |
Q1 2020 | Mar 31, 2020 | $-0.27 | $-0.18 | +33.6% | ✓ BEAT |
Q3 2019 | Sep 30, 2019 | — | $-0.18 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.23 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.23 | — | — |
Q1 2018 | Mar 31, 2018 | — | $-0.28 | — | — |
Q3 2017 | Sep 30, 2017 | — | $-0.28 | — | — |
Q1 2017 | Mar 31, 2017 | — | $-0.25 | — | — |
Q3 2016 | Sep 30, 2016 | — | $-0.12 | — | — |
Q1 2016 | Mar 31, 2016 | — | $-0.22 | — | — |
Q3 2015 | Sep 30, 2015 | — | $-0.25 | — | — |
Q1 2015 | Mar 31, 2015 | — | $-0.25 | — | — |
Q3 2014 | Sep 30, 2014 | — | $-0.20 | — | — |
Q1 2014 | Mar 31, 2014 | — | $-0.20 | — | — |
Latest News
Frequently Asked Questions about RENE.L
What is RENE.L's current stock price?
What is the analyst price target for RENE.L?
What sector is ReNeuron Group plc in?
What is RENE.L's market cap?
Does RENE.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RENE.L for comparison